Clinical trials: Renin-Angiotensin-Aldosterone System
Chronic Kidney Diseases, Hyperkalemia
Potassium Correction for RAAS Optimization in Chronic Kidney Disease
The goal of this placebo-controlled, double-blinded cross-over trial is to test whether patiromer, compared with placebo, better enables up-titration of RAAS-blocker treatment in patients with chronic kidney disease stage 3b/4.
- Conditions
- Chronic Kidney Diseases, Hyperkalemia, Hypertension
- Trial name
- PROMISE (NCT06256991)
- Testing
- Patiromer 8400 MG [Veltassa]
- Where
- Netherlands
- Volunteers
- 44 people
- Sponsor
- University Medical Center Groningen
COVID-19, SARS-CoV2 Infection
International Sites: Novel Experimental COVID-19 Therapies Affecting Host Response
The overarching goal of the Master Protocol is to find effective strategies for inpatient management of patients with COVID-19. Therapeutic goals for patients hospitalized for COVID-19 include hastening recovery and preventing…
- Conditions
- COVID-19, SARS-CoV2 Infection, Coronavirus Infection
- Trial name
- NECTAR (NCT05593770)
- Testing
- Fostamatinib
- Where
- 21 sites in Brazil, Germany and 3 more
- Volunteers
- 28 people
- Sponsor
- NEAT ID Foundation
Primary Aldosteronism, Primary Aldosteronism Due to Aldosterone Producing Adenoma
Ipsilateral and Contralateral Index for the Interpretation of Adrenal Vein Sampling (AVS) in Primary Aldosteronism
Adrenal vein sampling (AVS) is currently considered the gold standard for subtype diagnosis of primary aldosteronism (PA). However, the percentage of unsuitable procedures due to the unsuccessful cannulation of one of the two…
- Conditions
- Primary Aldosteronism, Primary Aldosteronism Due to Aldosterone Producing Adenoma, Primary Aldosteronism Due to Adrenal Hyperplasia (Bilateral)
- Trial name
- NCT04378387
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- University of Turin, Italy
COVID-19, SARS-CoV 2
COVID-19 Survival - The COVIVA Study
The COVID-19 pandemic poses a major and imminent challenge for health care systems regarding patient triage and allocation of limited resources worldwide.
- Trial name
- COVIVA (NCT04366765)
- Where
- Switzerland
- Volunteers
- 1,325 people
- Sponsor
- University Hospital, Basel, Switzerland
Hypertension, Stress, Psychological
Effectiveness of Prazosin on the Urinary Sodium Excretion Response to Mental Stress
High blood pressure, or hypertension, is a serious problem in the African-American (AA) population which affects nearly 7 of every 10 AAs in our area.
- Conditions
- Hypertension, Stress, Psychological, Blood Pressure
- Trial name
- NCT02431936
- Testing
- Prazosin
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Augusta University
Preeclampsia, Type 1 Diabetes
Urine-plasminogen as a Predictor for Development Of Preeclampsia in Pregnant Women With Type 1 Diabetes Mellitus
A tonic active epithelial Na+ channel (ENaC) in pre-eclampsia (PE) escaped normal hormonal control may offer an attractive explanatory model for the pathophysiology of established PE. The channel is activated by plasmin.
- Trial name
- NCT01821053
- Where
- Denmark
- Volunteers
- 85 people
- Sponsor
- Odense University Hospital
Salt Sensitivity of Blood Pressure, High Blood Pressure
Effect of an Isolevuglandin Scavenger on Salt Sensitivity of Blood Pressure and Immune Cell Activation in Humans
Hypertension is the leading cause of preventable deaths globally, driven by complications such as myocardial infarction, stroke, heart failure, and kidney disease.
- Conditions
- Salt Sensitivity of Blood Pressure, High Blood Pressure, Inflammation, Renin-Angiotensin-Aldosterone System
- Trial name
- NCT07602166
- Testing
- 2-hydroxybenzylamine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Vanderbilt University Medical Center
Arterial Stiffness, Renin Angiotensin Aldosterone System
RAAS and Arterial Stiffness in SCI
The study is examining differences in central arterial stiffness, orthostatic changes in blood pressure, norepinephrine, and plasma renin in individuals with spinal cord injury compared with age-matched uninjured controls.
- Conditions
- Arterial Stiffness, Renin Angiotensin Aldosterone System, Orthostatic Hypotension, Spinal Cord Injury
- Trial name
- NCT04510974
- Testing
- Spinal Cord Injury
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- James J. Peters Veterans Affairs Medical Center
Obstructive Sleep Apnea
Vitamin D and SGLT-2 Inhibitor in CPAP-naive Obstructive Sleep Apnea
The purpose of this study is to determine if vitamin D supplement and SGLT-2 inhibitor treatment combination can improve cardiovascular risks in patients with OSA and hypertension, on top of lifestyle modification, before…
- Trial name
- D3DOSA (NCT06690723)
- Testing
- Dapagliflozin (Forxiga), Vitamin D3 ( Colecalciferol), Vitamin D3 plus Dapagliflozin
- Where
- Malaysia
- Volunteers
- 160 people
- Sponsor
- University Malaysia Sarawak
Hyperaldosteronism
Kallikrein-kinin (KKS) and Renin-angiotensin-aldosterone System (RAAS) in Primary Aldosteronism
The tissue kallikrein-kinin (KKS) and renin-angiotension-aldosterone system (RAAS) had been implicated in regulating blood pressure and electrolyte homeostasis.
- Trial name
- NCT00155064
- Testing
- captopril, Losartan (drug)
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- National Taiwan University Hospital
Diabetic Nephropathy, Diabetic Retinopathy
Proteomic Prediction and Renin Angiotensin Aldosterone System Inhibition Prevention Of Early Diabetic nephRopathy In TYpe 2 Diabetic Patients With Normoalbuminuria
This is a prospective, multicenter, randomized, double blind, placebo-controlled and a prospective observational study. This study will be conducted at 15 study centers in various European countries.
- Trial name
- PRIORITY (NCT02040441)
- Testing
- Spironolactone, Standard care
- Where
- 15 sites in Belgium, Czechia and 8 more
- Volunteers
- 1,777 people
- Sponsor
- Peter Rossing
Hyperkalemia
Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND)
The purpose of this study is to assess the effects of patiromer compared with placebo on serum K+ in HF patients.
- Trial name
- DIAMOND (NCT03888066)
- Testing
- Patiromer
- Where
- 415 sites in United States, Argentina and 19 more
- Volunteers
- 1,195 people
- Sponsor
- Vifor Pharma, Inc.
Microalbuminuria
Low Dose Versus Aggressive Inhibition of the Renin-Angiotensin-Aldosterone (RAS) to Treat Microalbuminuria
The objective of the study is to assess the effect of standard versus aggressive inhibition of the renin-angiotensin system (RAS)in type 2 diabetic patients with microalbuminuria (MA) on; a)progression of microalbuminuria…
- Trial name
- END-IT (NCT00907374)
- Testing
- benazepril
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Charles Drew University of Medicine and Science
Hypertension, Metabolic Syndrome
The Study of Novel Dual Renin Angiotensin Aldosterone System (RAAS) Blockade; Valsartan/Aliskiren in African American Patients With Hypertension and the Metabolic Syndrome
Study purpose: African Americans with hypertension and markers of metabolic syndrome (small elevations in blood glucose, triglycerides and or weight) are at a high risk of cardiovascular (heart and blood vessel) problems.
- Trial name
- SAAVE (NCT01432106)
- Testing
- Aliskerin/Valsartan and Rampiril
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Michigan
Myocardial Infarction
Effect of Renin Angiotensin Aldosterone System Genetic Polymorphism on the Pharmacological Effect of Mineralocorticoid Receptor Antagonists in Patients With Myocardial Infarction
Early treatment of Myocardial Infarction patients with mineralocorticoid receptor antagonist with help reduces the incidence of cardiac remodeling and development into heart failure.
- Trial name
- NCT05873400
- Where
- Egypt
- Volunteers
- 102 people
- Sponsor
- Ain Shams University
COVID-19, SARS-CoV-2 Infection
Novel Experimental COVID-19 Therapies Affecting Host Response
The overarching goal of the Master Protocol is to find effective strategies for inpatient management of patients with COVID-19. Therapeutic goals for patients hospitalized for COVID-19 include hastening recovery and preventing…
- Conditions
- COVID-19, SARS-CoV-2 Infection, Coronavirus Infection
- Trial name
- NECTAR (NCT04924660)
- Testing
- TXA127, TRV027, Fostamatinib
- Where
- 51 sites in United States
- Volunteers
- 1,060 people
- Sponsor
- Sean Collins
Systemic Arterial Hypertension, Hypertension Resistant to Conventional Therapy
Renin-angiotensin-aldosterone System Polymorphisms in Resistant Hypertension and Adverse Cardiovascular Events
Renin-angiotensin-aldosterone system (RAAS) polymorphisms influence 24h arterial pressure fluctuation. Resistant systemic arterial hypertension (RSAH) has an increased risk of end organ damage and unfavourable prognosis, whereas…
- Conditions
- Systemic Arterial Hypertension, Hypertension Resistant to Conventional Therapy, Myocardial Infarction, Stroke
- Trial name
- GENHART (NCT01173029)
- Testing
- Anti-hypertensive drug treatment
- Where
- Brazil
- Volunteers
- 92 people
- Sponsor
- Universidade Gama Filho
Congestive Heart Failure, Low Cardiac Output
Losartan in Decompensated Heart Failure
The dual blockade of the renin-angiotensin-aldosterone system with an angiotensin-converting enzyme inhibitor and an angiotensin-receptor blocker used together in heart failure patients has been demonstrated to be beneficial.
- Trial name
- NCT01857999
- Testing
- Losartan
- Where
- Brazil
- Volunteers
- 21 people
- Sponsor
- InCor Heart Institute
Chronic Kidney Disease, Proteinuria
The Effect of Various Types of the Renin-angiotensin-aldosterone System Blockade on Proteinuria
The main purpose of the study is to compare the effects of three different types of RAAS blockade on 24 hours proteinuria in patients with non-diabetic chronic kidney disease.
- Trial name
- NCT01541267
- Testing
- aliskiren, eplerenon, telmisartan
- Volunteers
- 20 people
- Sponsor
- Medical University of Gdansk
Metabolic Syndrome
Renin Angiotensin Aldosterone System (RAAS) and Fibrinolysis in Humans: ACEi and PE5i
This study will measure the effect of the agent tadalafil on glucose and insulin homeostasis in people with metabolic syndrome in the presence and absence of an ACE inhibitor.
- Trial name
- NCT00750308
- Testing
- Ramipril, Tadalafil
- Volunteers
- 27 people
- Sponsor
- Vanderbilt University